Non–Small Cell Lung Cancer Coverage from Every Angle

Published Medical Literature

Use of Atezolizumab Plus Cabozantinib Under Study When Other Treatments Fail in NSCLC
Impact of Timely Comprehensive Genomic Profiling for Patients With Advanced NSCLC
Selecting First-Line Treatment in Metastatic NSCLC: Plasma Proteomes Take Center Stage
NSCLC and Malignant Pleural Effusion: Immune Checkpoint Inhibitor Plus Chemotherapy
Novel Radiomics Model May Predict Cardiac Outcomes After Radiotherapy for Lung Cancer
Stereotactic Ablative Radiotherapy for Early-Stage NSCLC With Interstitial Lung Disease
New Research Supports HERC5 as a Potential Metastasis Suppressor Gene in NSCLC
Lung Cancer Screening Eligibility: Is Pack-Year Smoking History an Inadequate Measure?
Role of Sublobar Resection in Early-Stage NSCLC Treatment
Immunotherapy vs Chemoimmunotherapy: Which Is Best for Older Adults With NSCLC?
Outcomes With Immunotherapy for Metastatic NSCLC: An FDA Pooled Analysis
Early Research Sheds Light on EGFR Protein Interface, a Potential Target for Therapies in Lung Cancer
Early-Phase Study Shows Activity of Lazertinib in Advanced EGFR-Mutated NSCLC
Monitoring Chemotherapy Use for NSCLC: A View From New Zealand
Using an Antidepressant to Improve Appetite and Energy in Patients With NSCLC
Phase III INSPIRE Trial: Iruplinalkib vs Crizotinib in Metastatic ALK-Positive NSCLC
Is FLT3 Expression Linked to Survival in Lung Cancer? Polish Researchers Say Yes
Combination Therapy of Pevonedistat and Docetaxel Shows Promise for Relapsed NSCLC: Phase II Study Results
Locally Advanced NSCLC: Pembrolizumab Plus Risk-Adapted Radiotherapy Under Study
Single-Site Oligometastatic Lung Cancer: Is Resection of the Primary Tumor Beneficial?
Phase III Trial Supports Use of Toripalimab Plus Chemotherapy in Stage III NSCLC
BRAF V600E–Mutant Circulating Tumor Cells and Resistance to BRAF Inhibition in NSCLC
Immune Checkpoint Inhibitor Pneumonitis: Assessing Risk Factors in Patients With Lung Cancer
Chemotherapy Plus Osimertinib in EGFR-Mutated NSCLC: Update From FLAURA2
NDR2 Expression: A Useful Biomarker in Predicting Metastatic Risk in Patients With NSCLC?
CNS Activity in NSCLC: Osimertinib Plus Chemotherapy vs Osimertinib Monotherapy
Is There a Link Between Regional Influenza Activity and Mortality Among Patients With NSCLC?
CANOPY-1: Adding Monoclonal Antibody to Immunotherapy Regimen in NSCLC
Selpercatinib vs Chemotherapy for RET Fusion–Positive NSCLC: Phase III Findings
Phase III Trial Supports Use of Amivantamab in NSCLC With EGFR Exon 20 Insertions
Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC: Who May Benefit?
Preoperative Splenic Area: Prognostic Biomarker for Early-Stage NSCLC?
Chemoradiotherapy and Immune Checkpoint Inhibitors in NSCLC: Insights on Impact of Induction
Dual Immunotherapy in the First-Line Setting of NSCLC: Ready for Prime Time?
Is Mass Spectrometry Useful in Detecting NSCLC Metastasis to Lymph Nodes?
2023 Lung Cancer Mortality Predictions in Europe
Lack of Success for Immunotherapy in Lung Cancer: Could the Reason Be Ineffective Priming of Cytotoxic T Lymphocytes?
Lorlatinib Continues to Outperform Crizotinib in 36-Month CROWN Follow-Up
RNA Modification and Tumor Immunity in Lung Cancer: Predicting Outcomes With Neoadjuvant Immunotherapy
Early Trial Results With Telisotuzumab Vedotin Plus Erlotinib in c-MET–Positive Lung Cancer
Can Predictive Models Determine 30-Day Mortality for Patients With Lung Cancer?
Streamlining the Process for Obtaining Next-Generation Sequencing Results in NSCLC
The Role of Postoperative Intensity-Modulated Radiation Therapy for Incompletely Resected NSCLC
How Oncogene-Driven Lung Cancer May Impact Pregnancy and Motherhood
5-Year Follow-up of KEYNOTE-042: Pembrolizumab Versus Chemotherapy in NSCLC
Can Artificial Intelligence Be Used to Predict the Presence of ALK Rearrangement in Lung Cancer?
PEARLS/KEYNOTE-091: Adjuvant Pembrolizumab in Completely Resected Stage IB–IIIA NSCLC
CT-Based Versus Minimal Follow-up for Patients With Resected NSCLC: Difference in Survival?
Are People Living With HIV at Increased Risk for Lung Cancer?
Can Immunotherapy After Chemoradiotherapy Improve Outcomes in Clinical Stage III Lung Cancer?
Early-Phase Trial Update on Use of Selpercatinib in RET Fusion–Positive NSCLC
Impact of Using Different Glomerular Filtration Rate Equations on Carboplatin Dosing in Lung Cancer
Clinical Validation of AI Models May Help Streamline Radiotherapy Planning in NSCLC
Research on the Biologic Mechanism Underlying Acquired Osimertinib Resistance in NSCLC
Modifiable Health System–Level Barriers Contribute to Lung Cancer Disparities
Can Artificial Intelligence Be Used to Develop a Decision Support Tool for Radiotherapy in NSCLC?
Phase III Trial of Aumolertinib Versus Gefitinib in EGFR-Mutated NSCLC
Trial Update on Tiragolumab Plus Atezolizumab as First-Line Treatment of NSCLC
CNS Metastasis From NSCLC: Discrepancies Between Public and Private Care in Brazil
Newer USPSTF Guidelines: Are More Black Patients Being Screened for Lung Cancer?
CheckMate 816: Nivolumab Plus Chemotherapy for Resectable NSCLC
Prolonged, Low-Level Exposure to Radon and Lung Cancer in Uranium Miners
Research Shows Anticancer Potential of Natural Compound Found in Barberry Plants
Novel Approach to Detecting Lung Cancer at the Cellular Level Under Study by Penn Medicine Researchers
Lung Cancer Risk: Study Identifies Potential Mechanism in Patients With a Smoking History
Hypofractionated Proton Therapy Plus Chemotherapy for Locally Advanced Lung Cancer
NOP56 and mTOR Cooperation Mechanism in KRAS-Mutant Lung Cancer
Researchers Explore Novel Process for Predicting Lung Cancer Recurrence
Radiation Therapy for NSCLC: Are There Racial Differences in Treatments and Side Effects?
PPDPF Overexpression: An Avenue for Further Research in Lung Cancer?
Treatment After Osimertinib Discontinuation in Real-World Setting of Metastatic NSCLC
Common Genes Associated With Overall Survival in NSCLC
Trends in the Cost of Agents Used to Treat Metastatic NSCLC
Early Research May Support Targeting PGM3 in Lung Cancer With Concurrent Mutations
How Effective Is Cell-Free ctDNA Profiling in Managing Advanced Lung Cancer?
Understanding Resistance to KRAS Inhibitors in Patients With NSCLC
Can Driver Genetic Alterations Predict Survival in Advanced Lung Adenocarcinoma?
COVID-19 and NSCLC: How Resilient Are Patients With Advanced Lung Cancer?
Adjuvant Atezolizumab Versus Best Supportive Care in Resected Early-Stage NSCLC: IMpower010 Results
Use of Nintedanib/Docetaxel in Advanced Nonsquamous Lung Cancer: Phase III Trial Results
Does Bias Affect Overall Survival Reporting in ALK-Positive NSCLC Treated With Alectinib Versus Ceritinib?
Update From ALTER-L004: First-Line Anlotinib Plus Icotinib in EGFR-Mutated NSCLC
IMPACT Trial of Adjuvant Gefitinib in EGFR-Mutated NSCLC
Case Study in Advanced Lung Cancer: EML4-NTRK Gene Fusion and ALK Inhibitor Resistance
Is Neoadjuvant PD-1 Inhibition Plus Chemotherapy of Benefit in Locally Advanced NSCLC?
Phase II Trial Shows Activity of Poziotinib in HER2 Exon 20–Mutant NSCLC
Final Overall Survival Results From APOLLO of Aumolertinib in Advanced NSCLC
Phase II Study of Anlotinib Plus Doxetaxel for Relapsed NSCLC
Sintilimab Plus Pemetrexed and Platinum for NSCLC: Updated ORIENT-11 Study Results
Locally Advanced NSCLC: Outcomes With Metformin Plus Chemoradiotherapy
KEYNOTE-010 Update: Long-Term Benefits Continue With Pembrolizumab in NSCLC
Is Proton Beam Therapy Effective in Locally Controlling Early-Stage NSCLC?
Phase III ACTIVE Trial: Apatinib Plus Gefitinib as First-Line Treatment in NSCLC
How Does Stereotactic Ablative Radiotherapy Measure Up Against Surgery in Stage I NSCLC?
Is T-DXd Active Against HER2-Mutant NSCLC?
Docetaxel Plus Intercalated Erlotinib Versus Docetaxel Alone in Nonsquamous Lung Cancer
Can Neuronal Autoantibodies Influence Cognitive Impairment in Patients With Lung Cancer?
Early Detection of Primary Lung Cancer Using Low-Dose CT Screening and Risk of Brain Metastases
Stage III NSCLC: Diversity of Treatment Practices and Outcomes in Real-World Setting
Can the Combination of CDK4 and MEK Inhibitors Reduce Resistance to Lung Cancer Therapy?
RATIONALE 304: Tislelizumab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer
Can a Deep Learning Algorithm Predict the Risk of Pulmonary Nodules Becoming Cancerous?
Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer
Effective Combination Therapy for COVID-19 Featured in a Patient With Lung Cancer
Proof-of-Concept Trial of Chemotherapy Plus Immune Checkpoint Inhibitor in Unresectable NSCLC
CodeBreaK100: Sotorasib for KRAS-Mutated Lung Cancer
Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC
Nab-paclitaxel Monotherapy in EGFR-Mutated Advanced Lung Cancer
Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?
Rare Case of STRN-ALK Rearrangement in Lung Cancer
Comparing TKIs as First-Line Treatment in Japanese Patients With NSCLC
Novel Method to Predict Cardiovascular Mortality Risk at Lung Cancer Screening
ORIENT-12 Trial: Sintilimab Plus Standard Chemotherapy for Metastatic Lung Cancer
Lung Cancer Risk Prediction Models and Racial Disparities
Inhibition of ROS1 in NSCLC: Updated Integrated Analysis of Three Clinical Trials
Making Progress in Targeting KRAS in Non–Small Cell Lung Cancer
Neoadjuvant Combination Immunotherapy for Operable Lung Cancer: NEOSTAR Trial Update
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients With Lung Cancer
NSCLC With Brain Metastases: Concurrent Chemotherapy and Whole-Brain Radiotherapy
Can Osimertinib Plus Bevacizumab Improve Outcomes in Advanced EGFR T790M–Mutated Lung Cancer?
EGFR-TKI Therapy for Lung Cancer: Can Machine Learning Model Identify Patients Unlikely to Benefit?
CheckMate 9LA: First-Line Immunotherapy Plus Chemotherapy in NSCLC
Lung Cancer Screening Amid the COVID-19 Pandemic
Radiotherapy Dose Exposure Thresholds and Adverse Cardiac Events in Patients With NSCLC
Smoking Behavior in Patients With Early-Stage NSCLC Enrolled in Clinical Trial
Examining Treatment Resistance in RET Fusion–Positive NSCLC
Can Supertype B44 HLA Antigen Shape Tumor Response in NSCLC?
Neoadjuvant Chemoimmunotherapy for Resectable Stage IIIA NSCLC
Study Finds Ethnic Association With Oncogenic Mutations for Patients With Lung Carcinoma
Can Lung Microbiome Enrichment Improve Outcomes for Patients With Lung Cancer?
Combining Novel Monoclonal Antibody With Radiotherapy for NSCLC
Atezolizumab Plus VEGF Inhibition in Stage IV Lung Cancer
AURA3 Overall Survival Analysis: Osimertinib Versus Chemotherapy for Advanced Lung Cancer
Novel PD-1 Antibody Shows Activity in Advanced Lung Cancer
Osimertinib in Treatment of EGFR-Mutated NSCLC: From the ADAURA Trial
Comparing Risk Prediction Models in Lung Cancer Screening: Focus on Black Smokers
Does a History of Smoking Influence the Molecular Diversity of Lung Tumors?
Study Explores Adoptive Cell Therapy for Refractory NSCLC
Update on Population-Level Mortality Rates in Lung Cancer
Case Report: Lung Cancer and SARS-CoV-2–Related Microthrombi
Online Tool Under Study to Improve Adherence to Guideline-Concordant Care in NSCLC
Combination Immunochemotherapy in Locally Advanced or Metastatic NSCLC
Lung Cancer and COVID-19: Effect on Treatment Scheduling
Palbociclib Monotherapy for Advanced NSCLC With CDKN2A Alterations
HER2-Mutant Advanced Lung Cancer: Pyrotinib After Chemotherapy
Selecting Initial Therapy in NSCLC: First Step Is Histology
Palbociclib Plus Osimertinib Under Study in Tyrosine Kinase Inhibitor–Resistant NSCLC
NSCLC and Bone Metastases: Loading Doses of Ibandronate for Bone Pain
Erlotinib in the Treatment of Lung Cancer With Leptomeningeal Metastases
Durvalumab in Advanced Lung Cancer: Final Overall Survival Data From ATLANTIC Trial
Stereotactic Body Radiotherapy Plus Adjuvant Chemotherapy for Older Patients With Lung Cancer
ALEX Study Update on Alectinib for ALK-Positive Non–Small Cell Lung Cancer
Long-Term Outcomes With Pembrolizumab for NSCLC and Brain Metastases
Advanced NSCLC: Tepotinib for MET Exon 14 Skipping Mutation
First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer
Third-Generation EGFR Tyrosine Kinase Inhibitor in Lung Cancer
Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy
COVID-19 and Lung Cancer: Focus on ALK/ROS1 Inhibitors
Safety of Combination Triplet for Lung Cancer in KEYNOTE-189
Tumor-Infiltrating Lymphocytes in Metastatic Lung Cancer
EML4-ALK Mutations and Lorlatinib Treatment in Lung Cancer
Does Patients' Knowledge of Lung Cancer Diagnosis Improve Survival Outcomes?
Beyond Skin Cancer: BRAF Inhibition in Solid Tumors Including Lung Cancer
Can AXL Inhibitor Overcome Treatment Resistance in EGFR-Mutant Lung Cancer?
First-Line Treatment Outcomes in Metastatic NSCLC: Real-World Patterns
Locally Advanced NSCLC and COVID-19: Alternative Treatment Strategies
Locoregional Recurrent Versus de Novo Locally Advanced NSCLC: Patient Outcomes
Chemoradiotherapy Plus Pembrolizumab for Stage III Lung Cancer
Novel Algorithm for Selecting Patients for Lung Cancer Treatment: EGFR Mutations Are Key
Durvalumab in Unresectable NSCLC: Are Outcomes Affected by PD-L1 Expression?
Risk of ICU Admission in Patients With Lung Cancer
Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer: Quality-of-Life Outcomes
Early-Phase Trial Studies Capmatinib in Advanced NSCLC
Smoking Cessation Interventions During Lung Cancer Screening
Adding Pemetrexed to Bevacizumab in Advanced Nonsquamous Lung Cancer
Tumor Mutation Burden in Metastatic NSCLC: Predictive of Response to Pembrolizumab?
Antibiotics and Proton Pump Inhibitors May Affect Outcomes in Patients Treated for Metastatic Lung Cancer
Osimertinib in Patients With Lung Cancer Who Have Uncommon EGFR Mutations
Heat Shock Protein 90 Inhibitor in Lung Cancer: GALAXY Clinical Trials
Robotic Bronchoscopy for Pulmonary Biopsy
Does Adding Cetuximab to Radiotherapy Improve Survival in Unresectable Lung Cancer?
Mortality Benefits of CT Screening for Lung Cancer in High-Risk Persons
Gefitinib Alone and in Combination for Untreated EGFR-Mutated Lung Cancer
Are Patients Older Than 90 Candidates for Lung Cancer Treatment?
Pemetrexed and Carboplatin Plus TKI in Advanced EGFR-Mutant Lung Cancer
Early-Phase Studies of Entrectinib for the Treatment of NTRK Fusion–Positive Solid Tumors
Role of Bevacizumab in Patients With Advanced NSCLC With Liver Metastases
Predicting Toxicity in Patients With Lung Cancer Treated With Pemetrexed
Can Consumption of Dietary Fiber and Yogurt Lower the Risk of Lung Cancer?
First-in-Human Study of Lazertinib in EGFR-Mutated Advanced Lung Cancer
Can BCG Vaccination During Childhood Reduce the Risk of Subsequent Lung Cancer?
First-in-Class Pegilodecakin Plus Immunotherapy Under Study in Lung Cancer
Bevacizumab Plus Erlotinib or Erlotinib Alone in EGFR-Mutated Lung Cancer
How Accurate Are Chest X-rays in Detecting Lung Cancer?
ASCEND-7 Trial: Use of Ceritinib for ALK-Positive Lung Cancer
Researchers Study Possible Link Between E-Cigarette Smoke and Lung Cancer
Researchers Study Possible Link Between E-Cigarette Smoke and Lung Cancer
Long-Term Survival With Nivolumab in Advanced Lung Cancer
Extended Follow-up From the National Lung Screening Trial
Insurance and Mortality in Lung and Other Cancers
Early Palliative Care and Survival in Patients With Advanced Lung Cancer
Oral Nelfinavir With Chemoradiotherapy for Locally Advanced Lung Cancer
Does Corticosteroid Use Affect Outcomes With Checkpoint Inhibitors in NSCLC?
Risk of HBV Reactivation During Therapy for Non–Small Cell Lung Cancer
Is Pembrolizumab of Benefit in Oligometastatic Lung Cancer After Local Ablative Therapy?
Nivolumab for Advanced Lung Cancer: 5-Year Survival
IMpower130 Supports Atezolizumab Inclusion in Stage IV Lung Cancer Therapy
Is Biennial Lung Cancer Screening Safe and Effective?
How an Intervention Trial Addressed Racial Disparities in Treatment of Early-Stage Cancers
Does Stereotactic Body Radiotherapy Enhance the Effect of Immunotherapy for Lung Cancer?
Is Lung Cancer Screening Effective in the Community Setting?
Statin Use After Radiotherapy for Survivors of Thoracic Cancer
Utility of Educational Video Regarding Lung Cancer Screening
Cardiovascular Toxicity in Patients Treated With Radiotherapy for Lung Cancer
Adding Erlotinib to Bevacizumab in EGFR-Positive Lung Cancer
Adding Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC
Innovative Drug Delivery System in Lung Cancer: Combining Quantum Dots and TKIs
Lifetime Incidence of Brain Metastasis in Elderly Survivors of Lung Cancer
Combining Plasma and Tissue Genotyping in EGFR-Mutant Lung Cancer
Five-Fraction Stereotactic Body Radiation Therapy for Centrally Located Lung Tumors
Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness
Chronic Opioid Use in Older Lung Cancer Survivors
Transformation of NSCLC to Small Cell Lung Cancer
Combination Therapy May Be Key to Treating KRAS-Mutant NSCLC
Immunotherapy for Advanced Lung Cancer: Is Tumor Mutational Burden Linked to Response?
Stereotactic Ablative Radiotherapy for Inoperable Early-Stage Lung Cancer
Does Prophylactic Cranial Irradiation Extend Survival in Locally Advanced Lung Cancer?
Shared Decision-Making in Lung Cancer Treatment: Patient Priorities and Preferences
Can MET Copy Number Predict TKI Resistance in EGFR -Mutant NSCLC?
Immunotherapy for Patients With NSCLC and HIV Infection
New Combination Therapy for NSCLC Tested in Phase II Trial
Tisotumab Vedotin Exhibits Antitumor Activity in NSCLC, Among Other Cancers
Pembrolizumab Versus Platinum-Based Chemotherapy in Advanced NSCLC
System-Based Intervention Designed to Reduce Racial Disparities in Lung Cancer Treatment
Does Afatinib Improve Outcomes in HER2-Mutant Lung Cancer?
Use of Lorlatinib in ALK-Positive NSCLC
Tumor Mutation Burden as Prognostic Biomarker in Non–Small Cell Lung Cancer
16-Year Trends in Aggressive End-of-Life Care in Patients With Lung Cancer
Variables Influencing Overall Survival in ALK-Positive NSCLC
SELECT Trial: Adjuvant Erlotinib in Resected EGFR-Mutant NSCLC
Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC
Does Pulmonary Fibrosis Increase the Risk of Pneumonitis Related to Anti–PD-1 Treatment?
Combination Epacadostat and Pembrolizumab in NSCLC
Could Thermal Ablation Rival Stereotactic Radiation Therapy in Early-Stage Lung Cancer?
Examining Emotional Effects on Long-Term Lung Cancer Survivors
JAVELIN Lung 200: Avelumab Versus Docetaxel in Advanced Lung Cancer
Surgery Type for Lung Cancer May Influence Later Opioid Use
Epigenetic Alterations and Tumor Mutational Burden in NSCLC
Does Early CT Screening for Lung Cancer Reduce Mortality?
Do Brain Metastases Affect Outcomes With Immunotherapy?
Can Salvage Treatment Improve Survival in Early-Stage Lung Cancer?
Impact of Neoadjuvant Erlotinib on Radical Resection Rate in Patients With NSCLC
Acquired Osimertinib Resistance in EGFR-Positive NSCLC
Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?
New Test May Help Risk Stratify Patients With NSCLC for Treatment
Osimertinib Treatment in T790M-Positive NSCLC With CNS Metastases
Should Cisplatin Accompany First-Line NSCLC Treatment in Elderly Patients?
Review Features Clinical Challenges of Personalized Treatment in NSCLC
ERBB Mutation as Predictive Biomarker for Afatinib Treatment in Lung Cancer
Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?
Addition of Biomarker Panel to Lung Cancer Screening: Can It Improve Detection of Disease?
Retrospective Analysis of Brain Metastases in Patients With Stage IV NSCLC
Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?
Brigatinib Active in Patients With ALK-Positive Lung Cancer
Overall Survival Benefit of Crizotinib in Patients With ALK-Positive NSCLC
How Accurate Are Lung Cancer Risk Models for Selecting Ever-Smokers for Screening?
Screening for Intracranial Disease in Patients With Lung Cancer Versus Breast Cancer
ASTRO Updates Guideline for Palliative Radiation Therapy for Lung Cancer
Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer
Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?
Risk of Brain Metastases in Patients With NSCLC
Updated ASTRO Guideline Focuses on Palliative Radiotherapy for Lung Cancer
Review Offers 2018 Roadmap for Treating Advanced Non–Small Cell Lung Cancer
Geographic Disparity Observed in Lung Cancer Deaths in Women
Hypoxia as Therapeutic Target in Non–Small Cell Lung Cancer
Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer
Update on Genomic Testing for Patients With Lung Cancer
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer
Risk of Second Primary Lung Cancer After Treatment of Primary Lung Tumor
ASCO Endorses Molecular Testing Guideline Update for TKI Treatment in Lung Cancer
Update on Treatment of Oligometastatic Lung Cancer
Targeted Next-Generation Sequencing for Predicting Treatment Response in Lung Cancer
Targeted Radiation vs. Surgery for Early-Stage Lung Cancer
Osimertinib in Treating CNS Metastases From Lung Cancer
Combination Therapy for Previously Untreated Advanced Lung Cancer
Chemoradiation Versus Radiation Alone in Elderly Patients With Lung Cancer
Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer
Radiosurgery vs. Whole-Brain Radiation for Brain Metastases in Patients With Lung Cancer
Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?
Osimertinib as First-line Treatment of EGFR-Mutant Advanced NSCLC
Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer
Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer
Dacomitinib vs. Gefitinib in First-Line Treatment of EGFR Mutation–Positive NSCLC
Gefitinib Plus Chemotherapy in the IMPRESS Trial: Final Overall Survival
Does Adding Motesanib to Paclitaxel/Carboplatin Improve Outcomes in East Asian Patients With Lung Cancer?
Icotinib vs. Chemotherapy in EGFR-Positive Lung Adenocarcinoma
Dabrafenib and Trametinib in BRAF V600E–Mutant Metastatic NSCLC
Hair Repigmentation and Response to Immunotherapy for NSCLC
Consolidative Radiotherapy Prior to Chemotherapy for Limited Metastatic NSCLC
Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?
First-Line Treatment With Osimertinib in EGFR Mutation–Positive Advanced NSCLC
Pathologic Nodal Staging Quality and Survival Differences in Non–Small Cell Lung Cancer
Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer
Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC
Fat Intake and Risk of Lung Cancer
COPD Treatment Initiative for Patients With Lung Cancer
Frequency of Lung Cancer in Never-Smokers in the UK
Surfactant Protein D and Clinical Outcomes in Lung Cancer
Use of Supplemental Vitamin B and Risk of Lung Cancer
Comparing Chemotherapy Regimens With Gemcitabine and Cisplatin in Advanced NSCLC
Combination Therapy With Apatinib in Resistant NSCLC
Updated Molecular Analyses in NSCLC Patients Treated With Erlotinib
Driver Mutations and Therapy Selection for Lung Adenocarcinoma
Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer
Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC
Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer
Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer
Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer
Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab
Alectinib and CNS Response in Resistant ALK-Positive Disease
Alectinib vs Crizotinib in ALK-Positive NSCLC
Potential Biomarker in Lung Squamous Cell Carcinoma
Early-Phase Trial of Vaccine in NSCLC
Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC
Local Ablative Therapy for Oligometastatic Lung Cancer
Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer
Chromosome Instability: Potential Prognostic Predictor in Lung Cancer
Multikinase Inhibitors in RET-Rearranged NSCLC
A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens and Sequences in Stage III NSCLC
Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer
Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous NSCLC
Proportion of Never-Smoker NSCLC Patients at Three Diverse Institutions
Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial
Management Strategies for Adverse Events Associated With EGFR TKIs in NSCLC
Treatment of Stage IIIA NSCLC
Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?
Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.